FindTrial
Sign In

A STUDY TO ASSESS URINE OMICS (PROTEOMICS, LIPIDOMICS & METABOLOMICS) IN HEALTHY INDIVIDUALS AND PATIENTS OF DYSLIPIDEMIA OF DIFFERENT DEHA PRAKRITI

A STUDY TO ASSESS URINE OMICS (PROTEOMICS, LIPIDOMICS & METABOLOMICS) IN DIFFERENT DEHA PRAKRITI (HEALTHY INDIVIDUALS AND PATIENTS OF DYSLIPIDEMIA) AN EXPLORATORY CLINICAL TRIAL - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098667
Enrollment
120
Registered
2025-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

All india institute of ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Group A will be used for recruitment of healthy participants aged 25-60 years of either sex. 2.Participants willing to give consent. 3.Group B -Participants aged 25-60 years of either sex 4.Fasting lipid profile consistent with any of the following: A.LDL cholesterol (borderline high to high, i.e., 100 to 189 mg per dl) B. Total cholesterol 200 mg per dl or higher. C.Triglycerides (borderline high to high, i.e., 150 to 499 mg per dl) D.Low HDL (less than 40 mg per dl) 5.No recent hospitalization or acute illness. 6.No current use of lipid-lowering medication or adequate washout (as per protocol 15 days).

Exclusion criteria

Exclusion criteria: Group B 1. Presence of secondary causes of dyslipidemia: 2.Diabetes mellitus with poor glycemic control (HbA1c more than 8%) 3. Individuals having level of LDL greater than 190 mg per dl and Sr. Tgl greater than 500mg per dl. 4. History of recent major cardiovascular events (within past 6 months): 5. Myocardial infarction 6. Use of lipid-lowering medications or corticosteroids within last 3 months and unable to undergo washout period. 7. Pregnant or lactating women. 8. Known allergy or hypersensitivity to triphala churna. 9. Significant psychiatric or neurological illness interfering with informed consent or compliance. 10. Inability or unwillingness to comply with study procedures or follow-up schedule.

Design outcomes

Primary

MeasureTime frame
1.Association of urine omics (proteomics, lipidomics, and metabolomics) in healthy individuals and dyslipidemia patients of different Prakriti. 2.Effect of Triphala Churna on serum lipid profile (total cholesterol, LDL, HDL, triglycerides) in dyslipidemia patients across different Prakriti types. 3.Effect of Triphala Churna on urine omics profiles (proteomics, lipidomics, and metabolomics) in dyslipidemia patients of different Prakriti types. Timepoint: BASELINE, 45 DAYS AND 90 DAYS—

Secondary

MeasureTime frame
1. Assessment of prakriti specific variation of other blood and urine parameters in healthy individuals and dyslipidemia patients of different Prakriti types. 2. Effect of Triphala Churna on other laboratory parameters in dyslipidemia patients. 3. Assessment of the Knowledge, attitude & practices of relevant life style modifications, Ayurveda practices & risks in patients of dyslipidemia. Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Shalini

All India Institute of Ayurveda

meera.samhita@aiia.gov.in9428570231

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026